Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenomic analysis of organoids from colorectal cancer peritoneal metastases uncovers a mechanism of resistance to doxorubicin

ABSTRACT: In this study, we generated patient-derived organoids (PDOs) from patients with colorectal cancer peritoneal mestasis and performed RNA- and ATAC-sequencing to study mechanisms for doxorubicin response.

ORGANISM(S): Homo sapiens

PROVIDER: GSE295009 | GEO | 2026/06/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenomic analysis of organoids from colorectal cancer peritoneal and liver metastases uncovers a mechanism of resistance to doxorubicin

Project description:In this study, we generated patient-derived organoids (PDOs) from patients with colorectal cancer peritoneal and liver mestases and performed RNA- and ATAC-sequencing to study mechanisms for doxorubicin response.

2026-06-16 | GSE294934 | GEO

Epigenomic analysis of organoids from colorectal cancer peritoneal metastases uncovers a mechanism of resistance to doxorubicin

Project description:Epigenomic analysis of organoids from colorectal cancer peritoneal metastases uncovers a mechanism of resistance to doxorubicin

| PRJNA1252455 | ENA

Epigenomic analysis of organoids from colorectal cancer peritoneal and liver metastases uncovers a mechanism of resistance to doxorubicin

Project description:Epigenomic analysis of organoids from colorectal cancer peritoneal and liver metastases uncovers a mechanism of resistance to doxorubicin

| PRJNA1252061 | ENA

Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer

Project description:Peritoneal carcinomatosis is a common yet deadly manifestation of gastrointestinal cancers, with few effective treatments. To identify targetable determinants of peritoneal metastasis, we focused on appendiceal adenocarcinoma (AC), a gastrointestinal cancer that metastasizes almost exclusively to the peritoneum. Current treatments are extrapolated from colorectal cancer (CRC), yet AC has distinct genomic alterations, mucinous morphology and peritoneum restricted metastatic pattern. Further, no stable preclinical models of AC exist, limiting drug discovery and representing an unmet clinical need. We establish a first-in-class stable biobank of 16 long-term cultured AC patient-derived organoids (PDOs), including 3 matched primary AC-peritoneal carcinomatosis (AC-PC) pairs. By enriching for cancer cells, AC PDOs enable accurate genomic characterization relative to paucicellular AC tissue. We establish an organoid orthotopic intraperitoneal xenograft model that recapitulates diffuse peritoneal carcinomatosis and show that PC-organoids retain increased metastatic capacity, decreased growth factor dependency and sensitivity to standard of care chemotherapy relative to matched primary AC organoids. Single cell profiling of AC-PC pairs reveals dedifferentiation from mucinous differentiated states in primary AC into intestinal stem cell and fetal progenitor states in PC, with upregulation of oncogenic signaling pathways. Through hypothesis-driven drug testing, we identify RAS inhibitor RMC-7977 and Wnt-targeting tyrosine kinase inhibitor WNTinib as novel, clinically actionable strategies to more effectively target AC-PC.

2026-04-29 | GSE303732 | GEO

Gene expression profiling of tumor organoids of colorectal liver metastases.

Project description:We have performed gene expression profiling of patient-derived tumor organoids (PDOs) and tissue samples of resected liver metastases from patients with metastatic colorectal cancer.

2026-04-20 | GSE294511 | GEO

Modeling Lung Adenocarcinoma Metastases Using Patient-Derived Organoids

Project description:Approximately 50% of patients with surgically resected early-stage lung cancer develop distant metastasis. At present, there is no in vivo metastasis model to investigate the biology of human lung cancer metastases. Using well-characterized patient-derived organoids (PDOs) from patients with lung adenocarcinoma (LUAD), we establish an in vivo metastasis model that preserves the biologic features of human LUAD metastases. Results of whole-genome and RNA sequencing performed in this study establish that our in vivo PDO metastasis model can be used to study clonality and tumor evolution and to identify biomarkers related to organotropism. Investigation of the response of KRASG12C PDOs to Sotorasib demonstrates that the model can examine the efficacy of treatments to suppress metastasis and identify mechanisms of drug resistance. Finally, our PDO model cocultured with autologous peripheral blood mononuclear cells can potentially be used to determine the optimal immune-priming strategy for individual patients with LUAD.

2024-09-12 | GSE276387 | GEO

Detoxifying doxorubicin

Project description:Detoxifying doxorubicin

| PRJNA422761 | ENA

Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.

Project description: Not available

| S-EPMC6771632 | biostudies-literature

Single-cell sequencing technology reveals the characteristics of the tumor microenvironment in gastric cancer and its peritoneal metastases

Project description:To analyze the tumor microenvironment characteristics of gastric cancer and its peritoneal metastases, we collected fresh surgical specimens pathologically confirmed as gastric cancer and peritoneal metastases, and performed single-cell sequencing.

2026-01-14 | GSE308231 | GEO

Prognostic Values of Immune Landscape in Ras-Mutant Colorectal Cancer Peritoneal Metastases

Project description:The peritoneal metastasis (PM) in patients with colorectal cancer (CRC) associated with poor survival, especially in those with Ras mutations. However, knowledge on the mechanism of molecular biology in CRC peritoneal metastasis (CRCPM) is limited, and the impact of tumor immune microenvironment (TME) on PM pathogenesis and the prognosis of CRCPM remains unclear. Therefore, we characterized the TME of CRCPM and evaluated its potential diagnostic and prognostic values. This study involved 21 patients with metastatic CRC (mCRC), of whom 11 with CRCPM were classified into the experimental group and 10 with mCRC without PM (noCRCPM) were classified into the control group. Formalin-fixed and paraffin-embedded tissue of primary tumors from all patients was examined using the NanoString RNA sequencing system. The clinicopathological variables and TME biomarkers were compared using the chi-square test and Cox regression analysis. According to the results of multivariate analysis, a prognostic nomogram was generated, and its prediction ability was measured using the concordance index (C-index). Survival curves were generated using the Kaplan–Meier method, and survival comparison between groups was conducted using the log-rank test.

2022-10-01 | GSE198085 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data